b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="In-Process" Owner="NLM">\n        <PMID Version="1">31732916</PMID>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>06</Month>\n            <Day>01</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1699-3055</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>22</Volume>\n                    <Issue>7</Issue>\n                    <PubDate>\n                        <Year>2020</Year>\n                        <Month>Jul</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Clinical &amp; translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico</Title>\n                <ISOAbbreviation>Clin Transl Oncol</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Multiple antibodies targeting tumor-specific mutations redirect immune cells to inhibit tumor growth and increase survival in experimental animal models.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>1094-1104</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s12094-019-02235-3</ELocationID>\n            <Abstract>\n                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">T cell therapy for cancer involves genetic introduction of a target-binding feature into autologous T cells, ex vivo expansion and single large bolus administration back to the patient. These reprogrammed T cells can be highly effective in killing cells, but tumor heterogeneity results in regrowth of cells that do not sufficiently express the single antigen being targeted. We describe a cell-based therapy that simultaneously targets multiple tumor-specific antigens.</AbstractText>\n                <AbstractText Label="METHODS" NlmCategory="METHODS">High-affinity polyclonal rabbit antibodies were generated against nine different surface-related tumor-specific mutations on B16F10 cells. Unsorted splenic effector cells from syngeneic mice were incubated with a cocktail of the nine anti-B16F10 antibodies. These \'armed\' effector cells were used to treat mice previously inoculated with B16F10 melanoma cells.</AbstractText>\n                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The cocktail of nine antibodies resulted in dense homogeneous binding to histological sections of B16F10 cells. Five treatments with the armed effector cells and PD1 inhibition inhibited tumor growth and improved survival. Shortening the interval of the five treatments from every three days to every day increased survival. Arming effector cells with the four antibodies showing best binding to B16F10 cells even further increased survival.</AbstractText>\n                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study demonstrates that ex vivo arming a mixed population of immune effector cells with antibodies targeting multiple tumor-specific mutated proteins in conjunction with PD1 inhibition delayed tumor growth and prolonged survival in mice inoculated with an aggressive melanoma. A remarkably low total antibody dose of less than 5\xc2\xa0\xc2\xb5g was sufficient to accomplish tumor inhibition. Scaling up to clinical level may be feasible.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Shukla</LastName>\n                    <ForeName>G S</ForeName>\n                    <Initials>GS</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Surgery and University of Vermont Cancer Center, University of Vermont Larner College of Medicine, Burlington, VT, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Pero</LastName>\n                    <ForeName>S C</ForeName>\n                    <Initials>SC</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Surgery and University of Vermont Cancer Center, University of Vermont Larner College of Medicine, Burlington, VT, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Sun</LastName>\n                    <ForeName>Y -J</ForeName>\n                    <Initials>Y-</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Surgery and University of Vermont Cancer Center, University of Vermont Larner College of Medicine, Burlington, VT, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Mei</LastName>\n                    <ForeName>L</ForeName>\n                    <Initials>L</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Surgery and University of Vermont Cancer Center, University of Vermont Larner College of Medicine, Burlington, VT, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Zhang</LastName>\n                    <ForeName>F</ForeName>\n                    <Initials>F</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Vermont Genetics Network, University of Vermont, Burlington, VT, USA.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Biology, University of Vermont, Burlington, VT, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Sholler</LastName>\n                    <ForeName>G</ForeName>\n                    <Initials>G</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Pediatric Oncology Research, Helen DeVos Children\'s Hospital, Grand Rapids, MI, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Krag</LastName>\n                    <ForeName>D N</ForeName>\n                    <Initials>DN</Initials>\n                    <Identifier Source="ORCID">http://orcid.org/0000-0001-5355-5999</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Surgery and University of Vermont Cancer Center, University of Vermont Larner College of Medicine, Burlington, VT, USA. David.Krag@uvm.edu.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <GrantList CompleteYN="Y">\n                <Grant>\n                    <GrantID>P20GM103449</GrantID>\n                    <Agency>Institutional Development Award (IDeA)</Agency>\n                    <Country/>\n                </Grant>\n            </GrantList>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2019</Year>\n                <Month>11</Month>\n                <Day>16</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>Italy</Country>\n            <MedlineTA>Clin Transl Oncol</MedlineTA>\n            <NlmUniqueID>101247119</NlmUniqueID>\n            <ISSNLinking>1699-048X</ISSNLinking>\n        </MedlineJournalInfo>\n        <CitationSubset>IM</CitationSubset>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="N">Antibodies</Keyword>\n            <Keyword MajorTopicYN="N">Cancer</Keyword>\n            <Keyword MajorTopicYN="N">Cell therapy</Keyword>\n            <Keyword MajorTopicYN="N">Effector cells</Keyword>\n            <Keyword MajorTopicYN="N">Mutated proteins</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2019</Year>\n                <Month>08</Month>\n                <Day>30</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2019</Year>\n                <Month>10</Month>\n                <Day>18</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>11</Month>\n                <Day>17</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>11</Month>\n                <Day>17</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>11</Month>\n                <Day>17</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">31732916</ArticleId>\n            <ArticleId IdType="doi">10.1007/s12094-019-02235-3</ArticleId>\n            <ArticleId IdType="pii">10.1007/s12094-019-02235-3</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'